Here’s what you should know.
1. The company expects results in the second quarter of fiscal year 2017.
2. Researchers conducted a randomized, double-blind, placebo-controlled study of Bekinda in patients with acute gastroenteritis and gastritis.
3. If the FDA approves Bekinda, it would be the first 5-HT3 antiemtetic drug designed for acute gastroenteritis and gastritis available in the United States.
4. RedHill is conducting a phase II study for its 12 mg version. The lower dose can treat diarrhea-predominant irritable bowel syndrome. RedHill expects to report results in mid-2017.
More articles on gastroenterology:
Takeda completes Ariad Pharmaceutical acquisition following NY law firm investigation — 3 GI companies making waves
GI leader to know: Dr. Shahab Aftahi of Estrella Gastroenterology
Versant Ventures launches Jecure Therapeutics: 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.